Clene Reports Third Quarter 2025 Financial Results and Recent Operating Highlights
Clene (Nasdaq: CLNN) reported third quarter 2025 results and operational updates on CNM-Au8 programs for ALS, MS, and PD.
The company had $7.9M cash as of Sept 30, 2025, and says additional $1.2M raised extends runway into Q2 2026. Clene plans an NDA filing in Q1 2026 under an accelerated approval pathway, expects first patient dosing in the confirmatory Phase 3 RESTORE-ALS trial in H1 2026, and will request a Type C FDA meeting to review further ALS biomarker analyses in Q1 2026.
Clene (Nasdaq: CLNN) ha riportato i risultati del terzo trimestre 2025 e aggiornamenti operativi sui programmi CNM-Au8 per SLA, SM e PD.
La società aveva $7.9M di cassa al 30 settembre 2025 e afferma che ulteriori $1.2M raccolti estendono la runway fino al Q2 2026. Clene prevede una presentazione di NDA nel Q1 2026 nell’ambito di un percorso di approvazione accelerata, si aspetta la somministrazione al primo paziente nello studio di conferma di fase 3 RESTORE-ALS nel H1 2026, e presenterà una riunione di tipo C con la FDA per rivedere ulteriori analisi di biomarcatori ALS nel Q1 2026.
Clene (Nasdaq: CLNN) informó los resultados del tercer trimestre de 2025 y actualizaciones operativas sobre los programas CNM-Au8 para ELA, EM y EP.
La compañía tenía $7.9M en efectivo al 30 de septiembre de 2025, y afirma que los $1.2M adicionales recaudados extienden la runway hasta el Q2 2026. Clene planea una presentación de NDA en el Q1 2026 bajo una vía de aprobación acelerada, espera la dosificación del primer paciente en el ensayo de fase 3 RESTORE-ALS de confirmación en el H1 2026, y solicitará una reunión de tipo C con la FDA para revisar más análisis de biomarcadores de ELA en el Q1 2026.
Clene (Nasdaq: CLNN) 는 2025년 3분기 실적 및 ALS, MS, PD에 대한 CNM-Au8 프로그램의 운영 업데이트를 발표했다.
회사는 2025년 9월 30일 기준 현금이 $7.9M였고, 추가로 $1.2M를 조달해 현금 여력(runway)을 2026년 2분기까지 연장한다고 밝혔다. Clene은 가속 승인 경로에 따른 2026년 1분기 NDA 제출을 계획하고, 2026년 상반기에 확증적 3상 RESTORE-ALS 시험의 첫 환자 투여를 기대하며, ALS 바이오마커 분석을 추가로 검토하기 위해 2026년 1분기에 FDA 타입 C 회의를 요청할 것이다.
Clene (Nasdaq: CLNN) a publié les résultats du troisième trimestre 2025 et des mises à jour opérationnelles sur les programmes CNM-Au8 pour la SLA, la SEP et la MP.
L’entreprise disposait de $7.9M en liquidités au 30 septembre 2025 et indique que 1,2 M$ supplémentaires levés prolongent la runway jusqu’au Q2 2026. Clene prévoit un dépôt NDA au 1er trimestre 2026 dans le cadre d’une voie d’approbation accélérée, s’attend à la première administration chez le patient dans l’essai de phase 3 RESTORE-ALS de confirmation au 1er semestre 2026, et demandera une réunion de type C avec la FDA pour examiner d’autres analyses de biomarqueurs de la SLA au 1er trimestre 2026.
Clene (Nasdaq: CLNN) meldete Ergebnisse des dritten Quartals 2025 und operative Updates zu den CNM-Au8-Programmen für ALS, MS und PD.
Das Unternehmen verfügte zum 30. September 2025 über $7.9M Bargeld, und teilt mit, dass weitere $1.2M aufgenommen wurden, wodurch die Finanzierungslaufzeit bis ins Q2 2026 verlängert wird. Clene plant eine NDA-Einreichung im Q1 2026 im Rahmen eines beschleunigten Zulassungsverfahrens, erwartet die erste Patientendosierung in der bestätigenden Phase-3-RESTORE-ALS-Studie im H1 2026 und wird ein Typ-C-FDA-Meeting beantragen, um weitere ALS-Biomarker-Analysen im Q1 2026 zu besprechen.
Clene (Nasdaq: CLNN) أعلنت عن نتائج الربع الثالث من عام 2025 وتحديثات تشغيلية لبرامج CNM-Au8 لعلاج ALS وMS وPD.
كان لدى الشركة $7.9M نقدًا حتى 30 سبتمبر 2025، وتقول إن $1.2M إضافية جُمعت مدّدت خط التمويل حتى الربع الثاني من 2026. تخطط Clene لتقديم NDA في الربع الأول من 2026 بموجب مسار الموافقة المعجّلة، وتتوقع جرعة المريض الأولى في تجربة المرحلة الثالثة المؤكِّدة RESTORE-ALS في النصف الأول من 2026، وستطلب اجتماع من النوع C مع FDA لمراجعة مزيد من تحليلات مؤشرات ALS الحيوية في الربع الأول من 2026.
- Plans to submit an NDA in Q1 2026 under accelerated approval
- First patient dosing expected in H1 2026 for Phase 3 RESTORE-ALS
- Cash runway extended into Q2 2026 after $1.2M post-quarter raise
- R&D expense declined by ~22% year-over-year in Q3 2025
- Cash and cash equivalents of $7.9M as of Sept 30, 2025
- Net loss of $8.8M (Q3 2025) pressured quarterly results
- Total other expense rose to $3.1M in Q3 2025 from $0.2M
Insights
FDA-directed biomarker analyses and an NDA plan sharpen pathway but limited cash creates near-term execution risk.
Clene has clear regulatory steps: the FDA recommended three biomarker analysis paths and a Type C meeting, and the company plans an NDA submission in
Execution depends on the forthcoming biomarker analyses being consistent with prior results and on completing the Type C meeting as planned; both are explicit preconditions to an accelerated approval filing. The company discloses cash and cash equivalents of
Watch for the Type C meeting outcome in
- As the U.S. Food and Drug Administration (FDA) proposed, Clene is concluding analyses of its ALS biomarker data with completion planned shortly
- The FDA advised Clene to request a Type C meeting to review these further ALS biomarker data analyses
- The Company plans to submit a New Drug Application (NDA) in the first quarter of 2026 under an accelerated approval pathway
- The Company expects to have the first patient dosed in the confirmatory Phase 3 RESTORE-ALS trial of CNM-Au8 in the first half of 2026
- The FDA and Clene participated in a Type B end of Phase 2 meeting in the third quarter of 2025 to discuss the Company’s MS clinical development program and ongoing plans for MS development of CNM-Au8
- Cash and cash equivalents of
$7.9 million as of September 30, 2025 - Cash runway extended into the second quarter of 2026, including
$1.2 million additionally raised following the third quarter close
SALT LAKE CITY, Nov. 13, 2025 (GLOBE NEWSWIRE) -- Clene Inc. (Nasdaq: CLNN) (along with its subsidiaries, “Clene” or the “Company”) and its wholly owned subsidiary Clene Nanomedicine Inc., a late clinical-stage biopharmaceutical company focused on revolutionizing the treatment of neurodegenerative diseases, including amyotrophic lateral sclerosis (ALS) and multiple sclerosis (MS), today announced its third quarter 2025 financial results and provided recent updates on its CNM-Au8 programs.
“The three potential biomarker paths that could be leveraged to increase the persuasiveness of our ALS data, as outlined by the FDA, include: a) the NfL analysis of our ongoing NIH-sponsored Expanded Access Program (EAP); b) additional ALS disease-specific biomarker changes (in addition to NfL) from the HEALEY ALS Platform Trial; and c) NfL analysis of subjects in the open-label extension (OLE) of the HEALEY ALS Platform Trial who were initially treated with placebo during the placebo-controlled portion of the trial and then received CNM-Au8 during the OLE,” said Rob Etherington, President and CEO of Clene. “The Company anticipates completing these data analyses shortly which could support the filing of an NDA using the accelerated approval pathway.”
Third Quarter 2025 and Recent Operating Highlights
CNM-Au8 for the treatment of ALS
Clene held a second Type C meeting with the FDA to review the long-term survival benefit from CNM-Au8 30 mg treatment compared to concurrently randomized controls from another HEALEY ALS Platform Trial regimen in the third quarter. Consistent with prior interactions, the FDA remains focused on demonstrated improvements in ALS disease-specific biomarkers to support a regulatory filing under the accelerated approval path, with analyses of overall survival potentially serving as confirmatory evidence.
The FDA recommended three potential paths that could be leveraged to increase the persuasiveness of the Company’s data, including analyses of other ALS disease-specific biomarkers and the effect of CNM-Au8 on NfL decline in various studies (NIH-sponsored EAP and HEALEY ALS Platform trial).
Further, as recommended by the FDA, Clene plans to request a Type C meeting with the FDA to review its data from these analyses, which meeting is expected to occur in the first quarter of 2026. Assuming the further ALS data analyses are consistent with previous results and incorporating FDA feedback, the Company plans to submit an NDA under an accelerated approval pathway.
Clene also anticipates having the first patient dosed in its confirmatory Phase 3 RESTORE-ALS trial of CNM-Au8 in the first half of 2026.
CNM-Au8 for the treatment of MS
In September 2025, the Company held a Type B end-of-Phase 2 meeting with the FDA, during which Clene and the FDA reviewed results from the Phase 2 VISIONARY-MS trial and explored proposed endpoints for the planned Phase 3 study focusing on cognition improvement as an adjunct to standard-of-care MS therapies. The FDA aligned with Clene acknowledging the limitations of the Expanded Disability Status Scale and expressed openness to considering other potential primary endpoints, including cognition, to evaluate broader treatment effects.
In September 2025, Clene presented the combined Phase 2 REPAIR-MS trial results across relapsing MS and non-active progressive MS during the 41st Congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS). CNM-Au8 improved the brain’s energy metabolism as evidenced by improvements to the NAD+/NADH ratio.
CNM-Au8 for the treatment of PD
In September 2025, Clene announced new preclinical data showing that CNM-Au8 improved key measures of cellular health in a novel dopaminergic neuron model of Parkinson’s disease (PD). This novel model for PD demonstrated CNM-Au8’s ability to improve mitochondrial health, restore cellular metabolism, reduce inflammation, and normalize dysregulated gene expression in both familial and sporadic PD. These new data support the continued development of CNM-Au8 as a treatment for PD.
Third Quarter 2025 Financial Results
Clene’s cash and cash equivalents totaled
Research and development expenses were
General and administrative expenses were
Total other expense was
Clene reported a net loss of
About Clene
Clene Inc. (Nasdaq: CLNN), along with its subsidiaries, “Clene” and its wholly owned subsidiary Clene Nanomedicine, Inc., is a late clinical-stage biopharmaceutical company focused on improving mitochondrial health and protecting neuronal function to treat neurodegenerative diseases, including amyotrophic lateral sclerosis, Parkinson’s disease, and multiple sclerosis. CNM-Au8® is an investigational first-in-class therapy that improves central nervous system cells’ survival and function via a mechanism that targets mitochondrial function and the NAD pathway while reducing oxidative stress. CNM-Au8® is a federally registered trademark of Clene Nanomedicine, Inc. The company is based in Salt Lake City, Utah, with R&D and manufacturing operations in Maryland. For more information, please visit www.clene.com or follow us on X (formerly Twitter) and LinkedIn.
About CNM-Au8®
CNM-Au8 is an oral suspension of gold nanocrystals developed to restore neuronal health and function by increasing energy production and utilization. The catalytically active nanocrystals of CNM-Au8 drive critical cellular energy producing reactions that enable neuroprotection and remyelination by increasing neuronal and glial resilience to disease-relevant stressors. CNM-Au8® is a federally registered trademark of Clene Nanomedicine, Inc.
Forward-Looking Statements
This press release contains “forward-looking statements” within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended, and Section 27A of the Securities Act of 1933, as amended, which are intended to be covered by the “safe harbor” provisions created by those laws. Clene’s forward-looking statements include, but are not limited to, statements regarding the timing of our analyses of potential biomarker paths, our plans to submit an NDA and the related timing, our expectations regarding the timing of the first patient dosing in the confirmatory Phase 3 RESTORE-ALS trial of CNM-Au8, the timing of our data collection and analyses, and our or our management team’s expectations, hopes, beliefs, intentions or strategies regarding our future operations. In addition, any statements that refer to projections, forecasts or other characterizations of future events or circumstances, including any underlying assumptions, are forward-looking statements. The words “anticipate,” “believe,” “contemplate,” “continue,” “estimate,” “expect,” “intends,” “may,” “might,” “plan,” “possible,” “potential,” “predict,” “project,” “should,” “will,” “would,” and similar expressions may identify forward-looking statements, but the absence of these words does not mean that a statement is not forward-looking. These forward-looking statements represent our views as of the date of this press release and involve a number of judgments, risks and uncertainties. We anticipate that subsequent events and developments will cause our views to change. We undertake no obligation to update forward-looking statements to reflect events or circumstances after the date they were made, whether as a result of new information, future events or otherwise, except as may be required under applicable securities laws. Accordingly, forward-looking statements should not be relied upon as representing our views as of any subsequent date. As a result of a number of known and unknown risks and uncertainties, our actual results or performance may be materially different from those expressed or implied by these forward-looking statements. Some factors that could cause actual results to differ include general market conditions, whether clinical trials demonstrate the efficacy and safety of our drug candidates to the satisfaction of regulatory authorities, or do not otherwise produce positive results which may cause us to incur additional costs or experience delays in completing, or ultimately be unable to complete the development and commercialization of our drug candidates; the clinical results for our drug candidates, which may not support further development or marketing approval; actions of regulatory agencies, which may affect the initiation, timing and progress of clinical trials and marketing approval; our ability to achieve commercial success for our drug candidates, if approved; our limited operating history and our ability to obtain additional funding for operations and to complete the development and commercialization of our drug candidates; and other risks and uncertainties set forth in “Risk Factors” in our most recent Annual Report on Form 10-K and any subsequent Quarterly Reports on Form 10-Q. In addition, statements that “we believe” and similar statements reflect our beliefs and opinions on the relevant subject. These statements are based upon information available to us as of the date of this press release, and while we believe such information forms a reasonable basis for such statements, such information may be limited or incomplete, and our statements should not be read to indicate that we have conducted an exhaustive inquiry into, or review of, all potentially available relevant information. These statements are inherently uncertain and you are cautioned not to rely unduly upon these statements. All information in this press release is as of the date of this press release. The information contained in any website referenced herein is not, and shall not be deemed to be, part of or incorporated into this press release.
Investor Contact: Kevin Gardner, LifeSci Advisors; kgardner@lifesciadvisors.com; 617-283-2856
CLENE INC.
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS
(In thousands, except share and per share amounts)
(Unaudited)
| Three Months Ended September 30, | Nine Months Ended September 30, | |||||||||||||||
| 2025 | 2024 | 2025 | 2024 | |||||||||||||
| Revenue: | ||||||||||||||||
| Product revenue | $ | — | $ | 65 | $ | 65 | $ | 173 | ||||||||
| Royalty revenue | 15 | 22 | 58 | 78 | ||||||||||||
| Total revenue | 15 | 87 | 123 | 251 | ||||||||||||
| Operating expenses: | ||||||||||||||||
| Cost of revenue | — | 18 | 20 | 52 | ||||||||||||
| Research and development | 3,513 | 4,471 | 8,508 | 14,490 | ||||||||||||
| General and administrative | 2,150 | 3,413 | 7,183 | 10,147 | ||||||||||||
| Total operating expenses | 5,663 | 7,902 | 15,711 | 24,689 | ||||||||||||
| Loss from operations | (5,648 | ) | (7,815 | ) | (15,588 | ) | (24,438 | ) | ||||||||
| Other income (expense), net: | ||||||||||||||||
| Interest income | 40 | 127 | 183 | 755 | ||||||||||||
| Interest expense | (649 | ) | (1,022 | ) | (1,936 | ) | (3,548 | ) | ||||||||
| Change in fair value of common stock warrant liabilities | (1,728 | ) | 697 | 267 | 956 | |||||||||||
| Change in fair value of derivative liabilities | (797 | ) | — | (89 | ) | — | ||||||||||
| Change in fair value of Clene Nanomedicine contingent earn-out liability | — | — | — | 75 | ||||||||||||
| Change in fair value of Initial Stockholders contingent earn-out liability | — | — | — | 10 | ||||||||||||
| Research and development tax credits and unrestricted grants | 5 | 27 | 216 | 339 | ||||||||||||
| Total other income (expense), net | (3,129 | ) | (171 | ) | (1,359 | ) | (1,413 | ) | ||||||||
| Net loss before income taxes | (8,777 | ) | (7,986 | ) | (16,947 | ) | (25,851 | ) | ||||||||
| Income tax expense | — | — | — | — | ||||||||||||
| Net loss | $ | (8,777 | ) | $ | (7,986 | ) | $ | (16,947 | ) | $ | (25,851 | ) | ||||
| Other comprehensive income: | ||||||||||||||||
| Unrealized loss on available-for-sale securities | $ | — | $ | 1 | $ | — | $ | (1 | ) | |||||||
| Foreign currency translation adjustments | 1 | 52 | 79 | 25 | ||||||||||||
| Total other comprehensive income | 1 | 53 | 79 | 24 | ||||||||||||
| Comprehensive loss | $ | (8,776 | ) | $ | (7,933 | ) | $ | (16,868 | ) | $ | (25,827 | ) | ||||
| Net loss per share – basic and diluted | $ | (0.85 | ) | $ | (1.22 | ) | $ | (1.77 | ) | $ | (4.00 | ) | ||||
| Weighted average common shares used to compute basic and diluted net loss per share | 10,284,674 | 6,557,839 | 9,549,661 | 6,467,771 | ||||||||||||
CLENE INC.
CONDENSED CONSOLIDATED BALANCE SHEETS
(In thousands, except share and per share amounts)
(Unaudited)
| September 30, 2025 | December 31, 2024 | |||||||
| ASSETS | ||||||||
| Current assets: | ||||||||
| Cash and cash equivalents | $ | 7,925 | $ | 12,155 | ||||
| Accounts receivable | — | 64 | ||||||
| Inventory | 61 | 68 | ||||||
| Prepaid expenses and other current assets | 4,687 | 3,870 | ||||||
| Total current assets | 12,673 | 16,157 | ||||||
| Restricted cash | 58 | 58 | ||||||
| Operating lease right-of-use assets | 3,225 | 3,643 | ||||||
| Property and equipment, net | 6,355 | 7,479 | ||||||
| TOTAL ASSETS | $ | 22,311 | $ | 27,337 | ||||
| LIABILITIES AND STOCKHOLDERS’ DEFICIT | ||||||||
| Current liabilities: | ||||||||
| Accounts payable | $ | 1,369 | $ | 1,240 | ||||
| Accrued liabilities | 4,894 | 7,766 | ||||||
| Operating lease obligations, current portion | 783 | 926 | ||||||
| Notes payable, current portion | 690 | 359 | ||||||
| Convertible notes payable, current portion | 570 | — | ||||||
| Total current liabilities | 8,306 | 10,291 | ||||||
| Operating lease obligations, net of current portion | 3,484 | 4,132 | ||||||
| Notes payable, net of current portion | 4,567 | 4,610 | ||||||
| Convertible notes payable | 11,218 | 10,816 | ||||||
| Common stock warrant liabilities | 4,274 | 4,541 | ||||||
| Derivative liabilities | 2,819 | 1,804 | ||||||
| TOTAL LIABILITIES | 34,668 | 36,194 | ||||||
| Commitments and contingencies | ||||||||
| Stockholders’ deficit: | ||||||||
| Common stock, and 8,089,565 shares issued and outstanding at September 30, 2025 and December 31, 2024, respectively | 1 | 1 | ||||||
| Additional paid-in capital | 286,562 | 273,194 | ||||||
| Accumulated deficit | (299,070 | ) | (282,123 | ) | ||||
| Accumulated other comprehensive income | 150 | 71 | ||||||
| TOTAL STOCKHOLDERS’ DEFICIT | (12,357 | ) | (8,857 | ) | ||||
| TOTAL LIABILITIES AND STOCKHOLDERS’ DEFICIT | $ | 22,311 | $ | 27,337 | ||||
FAQ
When does Clene (CLNN) plan to file an NDA for CNM-Au8?
What is Clene's (CLNN) cash runway and cash balance as of Sept 30, 2025?
When will Clene (CLNN) begin dosing patients in the Phase 3 RESTORE-ALS trial?
What FDA interactions did Clene (CLNN) report in Q3 2025 regarding ALS and MS?
How did Clene's (CLNN) Q3 2025 expenses compare to Q3 2024?
What clinical evidence did Clene (CLNN) present for CNM-Au8 in MS and PD in 2025?
